Program
Terbinafine
Also written as “MOB015B”, “terbinafine” and “Terbinafine Hydrochloride”.
Its studies are mostly in Onychomycosis · Erythema · Tinea Pedis · Mycoses · Fasting, led by 13 companies.
Drug pageTerbinafine: every studyMany companies study it; this page follows only the 33 they lead. All 46 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moberg Pharma ABits history only | 71 open or running | phase 3since Aug 4, 2016 | Mar 15, 2013 | none ahead |
| Novartis | 70 open or running | phase 3since Jun 30, 2005 | Nov 2, 1999 | none ahead |
| Almirallits history only | 30 open or running | phase 3since Sep 8, 2015 | Sep 8, 2015 | none ahead |
| Celtic Pharma Development Servicesits history only | 20 open or running | phase 3since Mar 19, 2010 | Mar 18, 2010 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jan 26, 2011 | Jan 26, 2011 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Nitric BioTherapeuticsits history only | 20 open or running | phase 2since Mar 1, 2010 | Mar 1, 2010 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Jan 17, 2013 | Jan 17, 2013 | none ahead |
| NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)its history only | 10 open or running | phase 1since Jun 3, 2008 | Jun 3, 2008 | none ahead |
| Onyx Axiomits history only | 11 open or running | phase 2since Nov 20, 2025 | Nov 20, 2025 | Jan 2028phase 2 · NCT07382427 |
| United Laboratoriesits history only | 10 open or running | phase 2since Jun 24, 2019 | Jun 24, 2019 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: no phase study in Candidiasis, OralFirst studyNCT00002394 · 30 enrolled · United States
- Jun 30, 20052 phase 3 studies in Tinea CapitisNCT00117767, NCT00117754
- Mar 2, 20072 phase 3 studies in OnychomycosisNCT00443820, NCT00443898
- Apr 10, 2007Phase 3 study in OnychomycosisNCT00459537 · 1,029 enrolled · Finland, France, Germany and more
- Sep 8, 2011Phase 3 study in Tinea PedisNCT01433107 · 290 enrolled · China
TargetBeta
“Squalene monooxygenase inhibitor; Squalene monooxygenase inhibitor”ChEMBL 37, by rule
“Terbinafine is a long-licensed, generic antifungal drug that inhibits squalene epoxidase (SQLE), an enzyme that may play a role in prostate cancer progression.”study text, by rule · the study
Studies
All 7 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01433107Tinea Pedis · China | 3 | Completed | Feb 2012 | 290 |
| NCT00459537Onychomycosis · Finland, France, Germany and more | 3 | Completed | Jan 2009 | 1,029 |
| NCT00443898Onychomycosis · United States, Canada, Iceland | 3 | Completed | Jun 2008 | 518 |
| NCT00443820Onychomycosis · United States, France, Germany | 3 | Completed | Jun 2008 | 526 |
| NCT00117767Tinea Capitis · United States | 3 | Completed | Mar 2006 | 720 |
| NCT00117754Tinea Capitis · United States | 3 | Completed | 720 | |
| NCT00002394Candidiasis, Oral · United States | – | Completed | 30 |
How it is read
Names in the registry
- “MOB015B”, 7 entries
- “terbinafine”, 4 entries
- “Terbinafine”, 3 entries
- “Terbinafine Hydrochloride”, 3 entries
- “Terbinafine HCl 250mg tablets”, 2 entries
Codes read as this program: P3058.
Conditions, from the studies’ own filings
- Onychomycosis, 19 studies
- Erythema, 2 studies
- Tinea Pedis, 2 studies
- Mycoses, 1 study
- Fasting, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.